Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  plerixafor
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 42 for your search:
Start Over
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 78
Sponsor: Pharmaceutical / Industry
Protocol IDs: MOZ11809, MSC12830, NCT01164475
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 78
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMD3100-3101, FHCRC-1985.00, NCT00103610
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 78
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMD3100-3102, 2005-003599-39, FHCRC-1986.00, NCT00103662
Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: EFC12482, MOZ14409, U1111-1131-0145, NCT01767714
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: 03-0349, NCT00241358
Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: 08-0897 / 201105349, NCT00733824
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 07-0227 / 201011796, NCT00512252
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: Other
Protocol IDs: 2007-0772, NCT00822770
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: 10-0910 / 201106039, NCT00906945
Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Other
Protocol IDs: 2009-0536, NCI-2012-01786, NCT01160354
A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Over 60
Sponsor: Other
Protocol IDs: SPON 845-10, 2010-021444-18, 10/MRE09/27, NCT01236144
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 2 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: DFI12860, 2010-019340-40, MOZ15609, NCT01288573
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: 09174, NCI-2011-00344, P50 CA107399, NCT01318317
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMD3100-C201, NCT00396266
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 78
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMD31002112, NCT00396331
The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMD31002113, NCT00444912
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).
Phase: Phase II
Type: Supportive care
Status: Completed
Age: 18 to 78
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMD3100-EU23, EudraCT number: 2006-00424729, NCT00665314
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: Pro00014563, NCT00901225
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: 09-0713 / 201103429, NCT00914849
Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: MC0889, NCI-2009-01328, 08-005644, NCT00998049
Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: CCM-002, NCT01037517
Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: IRB00027735, WCI1671-09, NCT01095757
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2310.00, NCI-2009-01562, 7157, P30CA015704, NCT01097057
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: 10-1154 / 201108083, NCT01158118
Start Over